PRKAG2
5'-AMP-activated protein kinase subunit gamma-2
Also known as: AAKG, AAKG2, AAKG2_HUMAN, CMH6, H91620p, WPWS
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q9UGJ0
- Gene
- PRKAG2
- Ensembl
- ENSG00000106617
- Chromosome
- 7
- Canonical length
- 569 aa
- Protein class
- Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins
- Subcellular location
- Nucleoplasm
OverviewNCBI Gene
AMP-activated protein kinase (AMPK) is a heterotrimeric protein composed of a catalytic alpha subunit, a noncatalytic beta subunit, and a noncatalytic regulatory gamma subunit. Various forms of each of these subunits exist, encoded by different genes. AMPK is an important energy-sensing enzyme that monitors cellular energy status and functions by inactivating key enzymes involved in regulating de novo biosynthesis of fatty acid and cholesterol. This gene is a member of the AMPK gamma subunit family. Mutations in this gene have been associated with Wolff-Parkinson-White syndrome, familial hypertrophic cardiomyopathy, and glycogen storage disease of the heart. Alternate transcriptional splice variants, encoding different isoforms, have been characterized. [provided by RefSeq, Jan 2015]
Canonical amino-acid sequenceUniProt
569 residues, UniProt reviewed canonical sequence.
>Q9UGJ0|PRKAG2
1 MGSAVMDTKK KKDVSSPGGS GGKKNASQKR RSLRVHIPDL SSFAMPLLDG DLEGSGKHSS
61 RKVDSPFGPG SPSKGFFSRG PQPRPSSPMS APVRPKTSPG SPKTVFPFSY QESPPRSPRR
121 MSFSGIFRSS SKESSPNSNP ATSPGGIRFF SRSRKTSGLS SSPSTPTQVT KQHTFPLESY
181 KHEPERLENR IYASSSPPDT GQRFCPSSFQ SPTRPPLASP THYAPSKAAA LAAALGPAEA
241 GMLEKLEFED EAVEDSESGV YMRFMRSHKC YDIVPTSSKL VVFDTTLQVK KAFFALVANG
301 VRAAPLWESK KQSFVGMLTI TDFINILHRY YKSPMVQIYE LEEHKIETWR ELYLQETFKP
361 LVNISPDASL FDAVYSLIKN KIHRLPVIDP ISGNALYILT HKRILKFLQL FMSDMPKPAF
421 MKQNLDELGI GTYHNIAFIH PDTPIIKALN IFVERRISAL PVVDESGKVV DIYSKFDVIN
481 LAAEKTYNNL DITVTQALQH RSQYFEGVVK CNKLEILETI VDRIVRAEVH RLVVVNEADS
541 IVGIISLSDI LQALILTPAG AKQKETETELocalizationUniProt · AlphaFold · HPA
Whether an antibody against PRKAG2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Secreted
- Secreted
- Yes
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.47
- Highest tissue expression
- 122 nTPM
Expression across tissuesHPA
Tissue
- heart muscle: 122 nTPM
- basal ganglia: 46 nTPM
- blood vessel: 39 nTPM
- urinary bladder: 38 nTPM
- liver: 32 nTPM
- small intestine: 25 nTPM
Single-cell type
- renal connecting tubule cells: 763 nCPM
- renal collecting duct principal cells: 742 nCPM
- prostatic glandular cells: 521 nCPM
- monocytes: 517 nCPM
- endometrial glandular cells: 480 nCPM
- endometrial luminal cells: 432 nCPM
Immune cell
- basophil: 26 nTPM
- neutrophil: 11 nTPM
- eosinophil: 11 nTPM
- memory B-cell: 9.6 nTPM
- classical monocyte: 9.4 nTPM
- naive CD8 T-cell: 7.3 nTPM
Brain region
- hippocampal formation: 35 nTPM
- cerebral cortex: 32 nTPM
- amygdala: 30 nTPM
- hypothalamus: 30 nTPM
- basal ganglia: 27 nTPM
- pons: 27 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about PRKAG2.
Disease | AllUniProt
Conditions PRKAG2 is implicated in, by any mechanism.
- Wolff-Parkinson-White syndrome (WPW) MIM:194200
- Cardiomyopathy, familial hypertrophic, 6 (CMH6) MIM:600858
- Glycogen storage disease of heart lethal congenital (GSDH) MIM:261740
Disease | GeneticClinVar
27 pathogenic / likely-pathogenic of 1,490 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Lethal congenital glycogen storage disease of heart
- Hypertrophic cardiomyopathy
- Hypertrophic cardiomyopathy 6
- Cardiovascular phenotype
- Cardiomyopathy
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.26
- gnomAD pLI
- 1
- gnomAD missense Z
- 1.65
- DepMap mean gene effect
- 0.04
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- ATP biosynthetic process
- cellular response to glucose starvation
- cellular response to nutrient levels
- fatty acid biosynthetic process
- glycogen metabolic process
- intracellular signal transduction
- positive regulation of gluconeogenesis
- regulation of carbon utilization
- regulation of cell cycle
- regulation of D-glucose import
- regulation of fatty acid metabolic process
- regulation of fatty acid oxidation
- regulation of glycolytic process
- sterol biosynthetic process
Molecular functions
- ADP binding
- AMP binding
- AMP-activated protein kinase activity
- ATP binding
- cAMP-dependent protein kinase inhibitor activity
- cAMP-dependent protein kinase regulator activity
- protein kinase activator activity
- protein kinase binding
- protein kinase regulator activity
- phosphorylase kinase regulator activity
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of PRKAG2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads PRKAG2 as an antibody target. Whether an autoantibody or antibody against PRKAG2 could matter depends on whether native PRKAG2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
PRKAG2 is annotated as secreted, so native PRKAG2 circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.
Annotation status
The present source text does not explicitly label PRKAG2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...